Krystal Biotech, Inc. KRYS Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s accrued expenses and other liabilities?
- Krystal Biotech, Inc. (KRYS) reported accrued expenses and other liabilities of -$6.31M in Q1 2026.
- How has Krystal Biotech, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Krystal Biotech, Inc.'s accrued expenses and other liabilities decreased by 270.8% year-over-year, from $3.7M to -$6.31M.
- What is the long-term trend for Krystal Biotech, Inc.'s accrued expenses and other liabilities?
- Over 2 years (2022 to 2025), Krystal Biotech, Inc.'s accrued expenses and other liabilities has grown at a 72.5% compound annual growth rate (CAGR), from $5.17M to $15.4M.